Pharmacogenomics Market Research Report – Global Forecast Till 2023

Pharmacogenomics Market Research Report – Global Forecast Till 2023

ID: MRFR/HC/0671-HCRR | December, 2017 | Region: Global | 90 pages | Half-Cooked Research Reports

Pharmacogenomics Market Research Report, By Technology (Microarray, Sequencing, Polymerase Chain Reaction) By Application (Cardiology, Neurological Disorders) By End Users (Hospitals, Research Organizations, Academic Institute) - Global Forecast till 2023

Market Scenario


Pharmacogenomics defines how genes can affect a person’s response to drugs. It is relatively a new field and combines pharmacology and genomics. The aim of pharmacogenomics is to develop effective and safe medications. Moreover by pharmacogenomics, drugs doses can be tailored to a person’s genetic makeup. The field of pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. According to the Organisation for Economic Co-operation and Development (2017), biotech R&D in the business enterprise sector was 11.3%, and 9.4% for U.S. and France respectively in 2014. Moreover, in 2016, according to the company BIOCOM AG, the total turnover for the Germany based biotech companies was USD 3.7 billion. The above data concludes that the biotechnology industry is expanding. This growing biotech sector along with the rising healthcare expenditures, and increasing interest for customized drugs will drive the market growth. However, lack of awareness and lack of consistency in pharmacogenomics products will restrain the market growth during the forecast period.


The global pharmacogenomics market is expected to grow at a ~CAGR of 5.8% during the forecast period.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers 


Figure 1:- Pharmacogenomics market share, by region

Pharmacogenomics Market


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Segmentation


The global pharmacogenomics market is segmented on the basis of technology, application, and end user.


On the basis of technology, the market is segmented into microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is sub-segmented into Sanger sequencing, pyrosequencing, next-generation sequencing, and others. On the basis of application, the market is segmented into oncology, cardiology, neurological disorders, and others. The oncology segment, by technology, is sub-segmented into breast cancer, lung cancer, and others. On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others 


Regional Analysis


The Americas dominate the global pharmacogenomics market owing to a well-developed healthcare sector and presence of developed economies like the U.S. and Canada. Moreover, increasing number of patients suffering from cardiovascular diseases and rising healthcare expenditure have boosted the growth of the market in America. In 2016, according to the Centres for Diseases Control and Prevention in the U.S., heart disease was the leading cause of death for both men and women. Moreover, it was also estimated that the healthcare expenditure for heart diseases in the U.S. reaches USD 200 billion each year. 


Europe is the second largest pharmacogenomics market, followed by Asia Pacific. Availability of funds for research and development along with government support and presence of huge patient population within the region will drive the market growth during the forecast period. Moreover, the presence of the developed economies like Germany and France within the region fuels the market growth. 


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China and presence of huge opportunities in the market drives the market. According to the Indian Brand Equity Foundation in 2016, the Indian biotech industry is estimated to reach USD 100 billion by 2025 from USD 7 billion in 2015 with a CAGR of 30.46%. 


On the other hand, the Middle East & Africa has the least share in the global pharmacogenomics market due to presence of poor economy, low per capita healthcare expenditure and stringent government policies especially in the Africa region. The majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. Moreover, developed economies like Dubai, Saudi Arabia, Dubai, besides others fuels the market growth within the Middle East & Africa region. 


Research Methodology
Global Pharmacogenomics Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players for global pharmacogenomics market


The key players for the global pharmacogenomics market are Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), and others. 

TABLE OF CONTENT    

Chapter 1.    Report Prologue    

Chapter 2.    Market Introduction    


      2.1    Definition    

      2.2    Scope of the Study    

            2.2.1    Research Objective    

            2.2.2    Assumptions    

            2.2.3    Limitations    

Chapter 3.    Research Methodology

      3.1    Introduction

      3.2    Primary Research    

      3.3    Secondary research    

      3.4    Market Size Estimation

Chapter 4.    Market Dynamics

      4.1    Drivers    

      4.2    Restrains

      4.3    Opportunities    

      4.4    Challenges

      4.5    Macroeconomic Indicators

      4.6    Technology Trends & Assessment            

Chapter 5.    Market Factor Analysis

      5.1    Porters Five Forces Analysis

            5.1.1    Bargaining Power of Suppliers    

            5.1.2    Bargaining Power of Buyers

            5.1.3    Threat of New Entrants    

            5.1.4    Threat of Substitutes    

            5.1.5    Intensity of Rivalry    

      5.2    Value Chain Analysis

      5.3    Investment Feasibility Analysis    

      5.4    Pricing Analysis

Chapter 6.    Global Pharmacogenomics Market, by Technology

     6.1    Introduction

      6.2    Microarray

Market Estimates & Forecast, 2017 – 2023

      6.3    Sequencing

Market Estimates & Forecast, 2017 – 2023

            6.3.1    Sanger Sequencing

            6.3.2    Pyrosequencing

            6.3.3    Next-Generation Sequencing

            6.3.4    Others

      6.4    Polymerase Chain Reaction

Market Estimates & Forecast, 2017 – 2023

      6.5    Others

Chapter 7.    Global Pharmacogenomics Market, by Application

     7.1    Introduction

      7.2    Oncology

Market Estimates & Forecast, 2017 – 2023

            7.2.1    Breast Cancer

            7.2.2    Lung Cancer

            7.2.3    Others

      7.3    Cardiology

Market Estimates & Forecast, 2017 – 2023

      7.4    Neurological Disorders

Market Estimates & Forecast, 2017 – 2023

      7.5    Others

Market Estimates & Forecast, 2017 – 2023

Chapter 8    Global Pharmacogenomics Market, by End User

      8.1    Introduction

      8.2    Hospitals and clinics

Market Estimates & Forecast, 2017 – 2023

      8.3    Research Organizations

Market Estimates & Forecast, 2017 – 2023

      8.4    Academic Institute

Market Estimates & Forecast, 2017 – 2023

      8.5    Others

Market Estimates & Forecast, 2017 – 2023

Chapter 9.    Global Pharmacogenomics Market, by Region

      9.1    Introduction

      9.2    America

            9.2.1    North America

                9.2.1.1    US

                9.2.1.1    Canada

            9.2.2    South America

      9.3    Europe

            9.3.1    Western Europe

                9.3.1.1    Germany

                9.3.1.2    France

                9.3.1.3    Italy

                9.3.1.4    Spain

                9.3.1.5    UK

                9.3.1.6    Rest of Western Europe

            9.3.2    Eastern Europe

      9.4    Asia Pacific

            9.4.1    Japan

            9.4.2    China

            9.4.3    India

            9.4.4    Australia

            9.4.5    Republic of Korea

            9.4.6    Rest of Asia Pacific

      9.5    The Middle East & Africa

            9.5.1    United Arab Emirates

            9.5.2     Saudi Arabia

            9.5.3    Oman

            9.5.4    Kuwait

            9.5.5    Qatar

            9.5.6    Rest of the Middle East & Africa

Chapter 10    Company Landscape    

      10.1    Introduction    

      10.2    Market Share Analysis    

      10.3    Key Development & Strategies    

            10.3.1    Key Developments    

Chapter 11    Company Profiles    

      11.1    Myriad Genetics, Inc.

            11.1.1    Company Overview    

            11.1.2    Product Overview    

            11.1.3    Financials    

            11.1.4    Key Developments

            11.1.5    SWOT Analysis    

      11.2    23andMe, Inc.    

            11.2.1    Company Overview    

            11.2.2    Product Overview    

            11.2.3    Financial Overview    

            11.2.4    Key Developments    

            11.2.5    SWOT Analysis    

      11.3    Pathway Genomics    

            11.3.1    Company Overview    

            11.3.2    Product Overview    

            11.3.3    Financial Overview

            11.3.4    Key Development    

            11.3.5    SWOT Analysis    

      11.4     GeneTech

            11.4.1    Company Overview    

            11.4.2    Product/Business Segment Overview    

            11.4.3    Financial Overview    

            11.4.4    Key Development    

            11.4.5    SWOT Analysis    

      11.5    GeneDx. 

            11.5.1    Overview

            11.5.2    Company Overview    

            11.5.3    Product Overview    

            11.5.4    Financial overview    

            11.5.5    Key Developments    

11.6    Future Science Group    

            11.6.1    Overview

            11.6.2    Company Overview    

            11.6.3    Product Overview    

            11.6.4    Financial Overview    

            11.6.5    Key Developments    

      11.7    Teva Pharmaceutical Industries Ltd.

            11.7.1    Overview    

            11.7.2    Product Overview    

            11.7.3    Financials    

            11.7.4    Key Developments    

            11.7.5    SWOT Analysis    

      11.8    Assurex Health, Inc.

            11.8.1    Overview    

            11.8.2    Product Overview    

            11.8.3    Financials    

            11.8.4    Key Developments    

            11.8.5    SWOT Analysis    

      11.9    Others        

Chapter 12    MRFR Conclusion    

      12.1    Key Findings    

            12.1.1    From CEO’s View Point    

            12.1.2    Unmet Needs of the Market    

      12.2    Key Companies to Watch    

      12.3    Prediction of Pharmaceutical industry

Chapter 13    Appendix



LIST OF TABLES

Table 1        Pharmacogenomics Industry Synopsis, 2017 – 2023

Table 2        Global Pharmacogenomics Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3        Global Pharmacogenomics Market by Region, 2017 – 2023, (USD Million)

Table 4        Global Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)

Table 5        Global Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 6        Global Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 7        North America Pharmacogenomics Market by Technology, 2017 – 2023, (USD Million)

Table 8        North America Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 9        North America Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 10    US Market by Technology, 2017 – 2023, (USD Million)

Table 11    US Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 12    US Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 13    Canada Market by Technology, 2017 – 2023, (USD Million)

Table 14    Canada Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 15    Canada Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 16    South America Market by Technology, 2017 – 2023, (USD Million)

Table 17    South America Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 18    South America Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 19    Europe Market by Technology, 2017 – 2023, (USD Million)

Table 20    Europe Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 21    Europe Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 22    Western Europe Market by Technology, 2017 – 2023, (USD Million)

Table 23    Western Europe Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 24    Western Europe Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 25    Eastern Europe Market by Technology, 2017 – 2023, (USD Million)

Table 26    Eastern Europe Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 27    Eastern Europe Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 28    Asia Pacific Market by Technology, 2017 – 2023, (USD Million)

Table 29    Asia Pacific Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 30    Asia Pacific Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)

Table 31    Middle East & Africa Market by Technology, 2017 – 2023, (USD Million)

Table 32    Middle East & Africa Pharmacogenomics Market by Application, 2017 – 2023, (USD Million)

Table 33    Middle East & Africa Pharmacogenomics Market by End Users, 2017 – 2023, (USD Million)



LIST OF FIGURES

Figure 1    Research Process

Figure 2    Segmentation for Global Pharmacogenomics Market

Figure 3    Segmentation Market Dynamics for Global Pharmacogenomics Market

Figure 4    Global Pharmacogenomics Market Share, by Technology 2016

Figure 5    Global Pharmacogenomics Market Share, by Application 2016

Figure 6    Global Pharmacogenomics Market Share, by End Users, 2016

Figure 7    Global Pharmacogenomics Market Share, by Region, 2016

Figure 8    North America Pharmacogenomics Market Share, by Country, 2016

Figure 9    Europe Pharmacogenomics Market Share, by Country, 2016

Figure 10    Asia Pacific Pharmacogenomics Market Share, by Country, 2016

Figure 11    Middle East & Africa Pharmacogenomics Market Share, by Country, 2016

Figure 12    Global Pharmacogenomics Market: Company Share Analysis, 2016 (%)

Figure 14    Myriad Genetics, Inc.: Key Financials

Figure 15    Myriad Genetics, Inc.: Segmental Revenue

Figure 16    Myriad Genetics, Inc.: Geographical Revenue

Figure 17    23andMe, Inc.: Key Financials

Figure 18    23andMe, Inc.: Segmental Revenue

Figure 19    23andMe, Inc.: Geographical Revenue 

Figure 20    Pathway Genomics: Key Financials

Figure 21    Pathway Genomics: Segmental Revenue

Figure 22    Pathway Genomics: Geographical Revenue

Figure 23    GeneTech: Key Financials

Figure 24    GeneTech: Segmental Revenue

Figure 25    GeneTech: Geographical Revenue

Figure 26    GeneDx. : Key Financials

Figure 27    GeneDx. : Segmental Revenue

Figure 28    GeneDx. :  Geographical Revenue

Figure 29    Future Science Group: Key Financials

Figure 30    Future Science Group: Segmental Revenue

Figure 31    Future Science Group: Geographical Revenue

Figure 32    Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 33    Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 34    Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 35    Assurex Health, Inc..: Key Financials

Figure 36    Assurex Health, Inc.: Segmental Revenue

Figure 37    Assurex Health, Inc.: Geographical Revenue